| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
4,150,000 |
| Market
Cap: |
537.01(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1294 - $1.78 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aptevo Therapeutics is a clinical-stage, research and development biotechnology company focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. Co.'s lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using Co.'s ADAPTIR™ modular protein technology platform. Co.'s preclinical candidate APVO442 was developed using its ADAPTIR-FLEX™ modular protein technology platform. The ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of improving the human immune system against cancer cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Taylor Daphne L |
SVP, CFO |
• – – |
2023-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,583 |
5,423 |
|
- |
|
| Taylor Daphne L |
SVP, CFOOfficer |
• – – |
2023-03-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,840 |
|
-27% |
|
| Lamothe Jeffrey G. |
EVP, COO |
• – – |
2023-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,666 |
12,692 |
|
- |
|
| White Marvin L |
President and CEO |
• • – |
2023-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,582 |
40,137 |
|
- |
|
| Kwon Soyoung |
SVP, GC, BD & Corp Affairs |
• – – |
2023-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,666 |
5,499 |
|
- |
|
| White Marvin L |
President and CEO |
• • – |
2023-01-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,791 |
30,555 |
|
- |
|
| Lamothe Jeffrey G. |
CFO |
• – – |
2023-01-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,834 |
9,026 |
|
- |
|
| Kunz Barbara Lopez |
Director |
– • – |
2022-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
298 |
1,012 |
|
- |
|
| Kwon Soyoung |
SVP, GC and Corporate Affairs |
• – – |
2022-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,833 |
1,833 |
|
- |
|
| Niederhuber John |
Director |
– • – |
2022-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
298 |
1,814 |
|
- |
|
| Abdun-Nabi Daniel |
Director |
– • – |
2022-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
298 |
8,108 |
|
- |
|
| Harsanyi Zsolt |
Director |
– • – |
2022-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
298 |
4,607 |
|
- |
|
| Grant Grady Iii |
Director |
– • – |
2022-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
298 |
1,012 |
|
- |
|
| White Marvin L |
President and CEO |
• • – |
2022-01-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,792 |
25,764 |
|
- |
|
| Lamothe Jeffrey G. |
SVP and CFO |
• – – |
2022-01-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,833 |
7,192 |
|
- |
|
| El-Hibri Fuad |
Director |
– • – |
2021-12-03 |
4 |
A |
$0.00 |
$0 |
I/I |
124,999 |
7,373 |
|
- |
|
| Tang Capital Partners Lp |
Exit Filing |
– – – |
2021-11-23 |
4 |
S |
$9.60 |
$10,368,236 |
I/I |
(921,336) |
0 |
|
64% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2020-11-06 |
4 |
B |
$20.63 |
$3,961,898 |
I/I |
174,277 |
1,760,000 |
1.5 |
43% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2020-11-05 |
4 |
B |
$14.22 |
$11,750,307 |
I/I |
625,723 |
1,585,723 |
1.5 |
63% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2020-11-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
323,325 |
|
119% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2020-11-04 |
4 |
B |
$10.63 |
$9,137,026 |
I/I |
636,675 |
960,000 |
1.5 |
119% |
|
| Maddux Randy Joe |
SVP Operations, CMO |
• – – |
2019-08-16 |
4 |
B |
$0.76 |
$19,000 |
D/D |
25,000 |
75,000 |
2.74 |
- |
|
| El-Hibri Fuad |
Director |
– • – |
2019-08-12 |
4 |
AB |
$0.76 |
$75,520 |
D/D |
100,000 |
1,124,536 |
|
- |
|
| El-Hibri Fuad |
Board of Directors |
– • • |
2019-07-29 |
4 |
B |
$0.83 |
$45,861 |
D/D |
55,015 |
1,024,536 |
0.01 |
- |
|
| El-Hibri Fuad |
Board of Directors |
– • • |
2019-07-23 |
4 |
B |
$0.90 |
$8,996 |
D/D |
10,000 |
969,521 |
0.01 |
- |
|
128 Records found
|
|
Page 2 of 6 |
|
|
